Denali Therapeutics Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
62.94 | 57.87 | 8.76% | 30.35 | +107.38% |
| P/S |
|
9.13 | 4.07 | 124.47% |
|
|
| P/BV |
|
2.93 | 9.39 | -68.85% |
|
|
| P/FCF |
|
-8.36 | 46.57 | -117.95% |
|
|
| Ev/Ebitda |
|
-16.35 | 17.62 | -192.75% |
|
|
| Ev/S |
|
8.9 | 4.37 | 103.72% |
|
|
| Ev/FCF |
|
-7.93 | 54.58 | -114.53% |
|
|
| E/P |
|
-0.0468 | 0.2164 | -121.62% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-54.45 | 20.15 | -370.25% | -349.44 | -84.42% |
| ROE |
|
-14.09 | -80.86 | -82.58% |
|
|
| ROA |
|
-12.59 | 6.71 | -287.45% |
|
|
| ROIC |
|
0 | 15.68 | -100% |
|
|
| ROS |
|
-43.94 | 10.56 | -516.29% |
|
|
| ROCE |
|
-19.08 | 18.05 | -205.7% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.2903 | 2.87 | -110.1% | -0.256 | +13.39% |
| Nеt Debt/Ebitda |
|
0.416 | 3.69 | -88.74% |
|
|
| Debt/Ratio |
|
0.0453 | 0.2643 | -82.87% |
|
|
| Debt/Equity |
|
0.0381 | 4.83 | -99.21% |
|
|
| Debt/Net Income |
|
-0.3597 | 6.45 | -105.58% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.31 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 6.4 | -100% | ||
| DSI |
|
0 | 0.7399 | -100% |
|
|
| Average dividend growth |
|
0 | -2.86 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.3 | -100% |
|
|
| Average percentage for payments |
|
0 | 77.61 | -100% |
|
|
| Difference from average difference in sector |
|
-1.31 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
1137.94 | 362.86 | 213.6% | ||
| Growth impulse Ebitda in 5 years |
|
-15.58 | 373.75 | -104.17% | ||
| Growth impulse Net Income in 5 years |
|
-26.51 | 454.84 | -105.83% | ||
| Growth impulse FCF in 5 years |
|
118.84 | 306.17 | -61.18% | ||
| Growth impulse EPS in 5 years |
|
-48.93 | 455.99 | -110.73% |
IP Score
3.68/10
